High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Open accessThe DOI matches its Crossref record.
Abstract
PURPOSE: Here we report the results of a nationwide cooperative study in the Netherlands on acute lymphoblastic leukemia (ALL) in children. The aim of the study was to improve the cure rate and to minimize side effects in a group of non-high-risk ALL patients, especially with regard to the CNS. A second aim was to study potential prognostic factors. METHODS: Children (age 0 to 15 years) with non-high-risk ALL (WBC count < 50 x 10(9)/L, no mediastinal mass, no B-cell phenotype, and no CNS involvement) were treated with a uniform protocol, ALL VI. The treatment protocol used 6-week induction regimen with three drugs (vincristine, dexamethasone, and asparaginase), three weekly doses of intravenous (IV) medium high-dose methotrexate (2 g/m2), and 2-year maintenance therapy that consisted of alternating 5-week periods of methotrexate and mercaptopurine and 2-week periods of vincristine and dexamethasone. In the first year of maintenance, triple intrathecal therapy was administered every 7 weeks. RESULTS: From December 1, 1984 until July 1, 1988, 291 children with ALL were diagnosed; 206 were categorized as non-high-risk (71%), and 190 were treated according to protocol ALL VI. At 8 years, the event-free survival (EFS) rate was 81% (SE = 3%) and survival rate 85% (SE = 2.9%); the median follow-up time was 7.3 years (range, 36 to 117 months). The CNS relapse rate was 1.1% (two of 184 patients who achieved a complete remission [CR]). The only factor found to be of negative prognostic importance in terms of EFS (P = .05) was a positive acid phosphatase reaction. CONCLUSION: For children with non-high-risk ALL, the combination of IV medium high-dose methotrexate (2 g/m2 times three), triple intrathecal therapy in the first year of maintenance treatment, and the use of dexamethasone for induction and pulses during maintenance treatment has proved to be highly effective, especially in the prevention of CNS relapse. A high cure rate was achieved without the use of anthracyclines, alkylating agents, and cranial irradiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
van Dongen, J. J., Seriu, T., Panzer-Grümayer, E. R., Biondi, A., Pongers-Willemse, M. J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W. A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04058-6 · Cited by 952
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 865
Pui, C.-H., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 832
Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C. M., Henze, G., Feldges, A., Zintl, F., et al. (2000) · PubMed · doi:10.1182/blood.v95.11.3310 · Cited by 602
Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.-D., Henze, G., Gadner, H., Odenwald, E., & Riehm, H. (2000) · Leukemia · doi:10.1038/sj.leu.2401973 · Cited by 531
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., & Pui, C.-H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380803 · Cited by 492
Mitchell, C. D., Richards, S. M., Kinsey, S. E., Lilleyman, J., Vora, A., Eden, T. O. B., & the Medical Research Council Childhood Leukaemia Working Party (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05509.x · Cited by 418
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Glucocorticoid use in acute lymphoblastic leukaemia
Inaba, H., & Pui, C.-H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70114-5 · Cited by 367
Mahoney, D. H., Shuster, J. J., Nitschke, R., Lauer, S. J., Steuber, C. P., Winick, N., & Camitta, B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1712 · Cited by 290
Möricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, F., Cazzaniga, G., Niggli, F., Aricò, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-670729 · Cited by 283
Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia
Strauss, A. J., Su, J. T., Dalton, V. M. K., Gelber, R. D., Sallan, S. E., & Silverman, L. B. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3066 · Cited by 252
Hartman, A., te Winkel, M. L., van Beek, R. D., de Muinck Keizer‐Schrama, S. M. P. F., Kemper, H. C. G., Hop, W. C. J., van den Heuvel‐Eibrink, M. M., & Pieters, R. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21942 · Cited by 203
“Patients were treated according to the ALL-9 protocol of the Dutch Childhood Oncology Group (DCOG), which was identical to the previously used ALL-6 protocol for the non-high-risk (NHR) patients [24].”
MethodAppel, I. M., den Boer, M. L., Meijerink, J. P. P., Veerman, A. J. P., Reniers, N. C. M., & Pieters, R. (2006) · Blood · doi:10.1182/blood-2005-06-2597 · Cited by 70
Self-citation
Metadata
- Authors
- Veerman, A. J., Hählen, K., Kamps, W. A., Van Leeuwen, E. F., De Vaan, G. A., Solbu, G., Suciu, S., Van Wering, E. R., & Van der Does-Van der Berg, A.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 911-918
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1925805959
- Cited by
- 204
- References
- 0
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.